Xiaoxiao Ge

Xiaoxiao Ge

Auto-generated profile, based on publicly available information

Xiaoxiao Ge

Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, P.R. China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2013 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
XGXiao-Xiao Ge
Xiao-Xiao Ge
MXMei-Yuan Xing
Mei-Yuan Xing
LYLan-Fang Yu
Lan-Fang Yu
PSPeng Shen
Peng Shen
Carotenoid Intake and Esophageal Cancer Risk: a Meta-analysis Carotenoids (lycopene, b-carotene);esophageal cancer;cancer risk;meta-analysis; This meta-analysis was conducted to evaluate the association between intake of carotenoids and risk of esophageal cancer. A systematic search using PubMed, Cochrane Library, Web of Science, Scopus, CNKI, and CBM (updated to 6 May 2012) identified ten articles meeting the inclusion criteria with 1,958 cases of esophageal cancer and 4,529 controls. Higher intake of beta-carotene, alpha-carotene, lycopene, beta-cryptoxanthin, lutein, and zeaxanthin reduced esophageal cancer risk with pooled ORs of 0.58 (95% CI 0.44, 0.77), 0.81 (95% CI 0.70, 0.94), 0.75 (95% CI 0.64, 0.86), 0.80 (95% CI 0.66, 0.97), and 0.71 (95% CI 0.59, 0.87), respectively. In subgroup analyses, beta-carotene showed protective effects against esophageal adenocarcinoma in studies located in Europe and North America. Alpha-carotene, lycopene, and beta-cryptoxanthin showed protection against esophageal squamous cell cancer. This meta-analysis suggested that higher intake of carotenoids (beta-carotene, alpha-carotene, lycopene, beta-cryptoxanthin, lutein, and zeaxanthin) is associated with lower risk of esophageal cancer. Further research with large-sample studies need to be conducted to better clarify the potentially protective mechanisms of carotenoid associations risk of different types of esophageal cancer.

19 March 2013 in Biomedical Reports
Verified
Journal Article
Closed access
PDF file
XGXiaoxiao Ge
Xiaoxiao Ge
XWXiao Wang
Xiao Wang
PSPeng Shen
Peng Shen
Prostate cancer is the second most frequently diagnosed type of cancer and the sixth leading cause of cancer mortality among males worldwide. The aim of this study was to investigate the association between the infection by herpes simplex virus type 2 (HSV‑2) or human herpesvirus 8 (HHV‑8) and the risk of prostate cancer. A systematic literature search was performed using PubMed, Cochrane Library, Web of Science, Scopus, CNKI and CBM. The association of HSV‑2 or HHV‑8 infection with the risk of prostate cancer was separately assessed. Estimates of the odds ratio (OR) with 95% confidence interval (CI) were pooled by the fixed‑ or random‑effects model. A total of 11 articles with 2,996 cases and 3,875 controls were included in this meta‑analysis. HSV‑2 infection was associated with increased prostate cancer risk (OR=1.209; 95% CI, 1.003‑1.456). Results of the stratified analysis suggested that such an association existed among participants from North and South America (OR=1.226; 95% CI, 1.000‑1.503). No significant correlation was observed in the HHV‑8 group (OR=1.106; 95% CI, 0.765‑1.598). Further investigations and large‑sample studies are required to elucidate the possible mechanism underlying viral carcinogenesis and the association between herpes virus infection and the risk of prostate cancer.

27 February 2013 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
LYLanfang Yu
Lanfang Yu
XGXiaoxiao Ge
Xiaoxiao Ge
SHSui Huang
Sui Huang
YWYanli Wang
Yanli Wang
PSPeng Shen
Peng Shen
Retroperitoneal squamous cell carcinoma (SCC) of unknown origin is uncommon. It is extremely rare when the primary site detected in the esophagus after 18 months. A 59‑year‑old female patient with waist pain was initially diagnosed as retroperitoneal metastatic SCC of occult origin. Six cycles of chemotherapy with cisplatin, paclitaxel and 5‑fluorou­racil were administered and clinical complete response was observed. The primary site was detected in the esophagus after 18 months and the overall survival (OS) was 28 months. To the best of our knowledge, this is the first case of esophageal squamous cell carcinoma (ESCC) initially presenting as a metastatic site with long progression‑free survival (PFS) and OS. In conclusion, the different biological characteristics and complete response to first‑line chemotherapy likely contribute to relatively long PFS and OS.